

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)

ATTORNEY'S DOCKET NUMBER

X-13980

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

10/522227INTERNATIONAL APPLICATION NO.
PCT/US2003/019890INTERNATIONAL FILING DATE
31 July 2003 (31.07.2003)PRIORITY DATE CLAIMED
09 August 2002 (09.08.2002)TITLE OF INVENTION: **BENZIMIDAZOLES AND BENZOTHAZOLES AS INHIBITORS OF MAP KINASE**

APPLICANT(S) FOR DO/EO/US: **Rosanne BONJOUKLIAN, Jose Eugenio DE DIEGO GOMEZ, Alfonso DE DIOS, Chafiq Hamdouchi HAMDOUCHI, Tiechao LI, Beatriz LOPEZ DE URALDE GARMENDIA, Michal VIETH, Jeremy Schulenburg YORK, Robert Dean DALLY, Miriam Filadelfa DEL PRADO CATALINA, Carlos JARAMILLO, Luisa Maria MARTIN CABREJAS, Carlos MONTERO SALGADO, Sheila PLEITE, Concepcion SANCHEZ-MARTINEZ, Timothy Alan SHEPHERD, and James Howard WIKEL**

Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:



1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.
11. ☒ A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 12. to 18. below concern document(s) or information included:

12. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☐ Assignment has been recorded at reel _____, frame _____.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A Sequence Listing, 1.821 Statement, and diskette.
17. ☒ A power of attorney with attachments.
18. ☒ Other items or information:

Please amend the first page of the specification by inserting the following cross-reference after the title:

"This is the national phase application, under 35 USC 371, for PCT/US2003/019890, filed 31 July 2003, which claims the benefit of EP 02380178.0, filed 09 August 2002, and US provisional application 60/421,939, filed 28 October 2002."

U.S. APPLICATION NO. (if known, see 37 CFR. 1.5) 10/522227		INTERNATIONAL APPLICATION NO. PCT/US2003/019890		ATTORNEY'S DOCKET NUMBER X-13980	
19. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Stage Fee = \$ 300.00 National Stage Search Fee = \$ 500.00 National Stage Examination Fee = \$ 200.00 TOTAL NATIONAL STAGE FEES \$1,000.00 (a) Application Length Fee Total Length (excluding sequence listings) <u>121</u> - 100 ÷ 50 x 250 = \$250.00 (b)				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE AMOUNT (a + b) =				\$ 1,250.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	12 -20=	0	X \$50.00	\$	
Independent claims	1 -3=	0	X \$200.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1,250.00	
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 1,250.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
TOTAL FEES ENCLOSED =				\$ 1,250.00	
				Amount to be refunded	\$
				charged	\$
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 05-0840 in the amount of \$1,250.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288 <u>21 January 2005</u> DATE <u>49,206</u> REGISTRATION NUMBER		 SIGNATURE Robert D. Titus NAME <u>(317) 277-3729</u> TELEPHONE NUMBER		 25885 PATENT TRADEMARK OFFICE	

IN THE UNITED STATES RECEIVING OFFICE (USRO)

10/522227

DT01 Rec'd PCT/PT 25 JAN 2005

Applicants: Rosanne BONJOUKLIAN
Jose Eugenio DE DIEGO GOMEZ
Alfonso DE DIOS
Chafiq Hamdouchi HAMDouchi
Tiechao LI
Beatriz LOPEZ DE URALDE GARMENDIA
Michal VIETH
Jeremy Schulenburg YORK
Robert Dean DALLY

Miriam Filadelfa DEL PRADO CATALINA
Carlos JARAMILLO
Luisa Maria MARTIN CABREJAS
Carlos MONTERO SALGADO
Sheila PLEITE
Concepcion SANCHEZ-MARTINEZ
Timothy Alan SHEPHERD
James Howard WIKEL

International Application No.: PCT/US2003/019890

Filed: 31 July 2003 (31.07.2003)

Invention: BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE

Lilly Reference: X-13980

Earliest Priority Date: 09 August 2002 (09.08.2002)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: EV 392094398 US

Date of Deposit: Jan. 25, 2005

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN Thomas
(Typed or printed name of person mailing paper)

Queen Thomas
(Signature of person mailing paper or fee)